Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Educational intervention development |
Develop and refinement of a film-based educational intervention in partnership with pregnant women and families affected by CMV |
3 years |
|
Secondary |
Proportion of women willing to be screened for CMV |
Proportion of women approached who are willing to have antenatal booking blood tested for CMV antibodies to determine serostatus |
1 year |
|
Secondary |
Proportion of women seronegative at antenatal booking |
Proportion of women who have no evidence of previous CMV infection at the time of antenatal booking |
1 year |
|
Secondary |
Proportion of women with primary CMV infection in the first trimester of pregnancy |
Proportion of women who have evidence of primary CMV infection within the first trimester of pregnancy |
1 year |
|
Secondary |
Proportion of seronegative willing to be randomised to receive educational intervention or treatment as usual |
Proportion of seronegative pregnant women willing to participate in feasibility study, which includes randomisation to the educational intervention or treatment as usual |
1 year |
|
Secondary |
Seroconversion rate |
Women will have a second blood sample tested at the end of pregnancy (between 34 weeks and delivery) to determine whether seroconversion has occurred. Seroconversion is the appearance of anti-CMV IgG antibodies in the serum of a person who did not have such antibodies previously. This will be the gold standard evidence for acquisition of primary infection and is the main outcome measure of the future main trial. |
18 months |
|
Secondary |
Proportion of infants with congenital CMV |
The proportion of infants with a positive test for CMV in the first 21 days of life |
2 years |
|
Secondary |
Measures of adherence |
Women in the treatment arm will be asked to a questionnaire to assess their perceptions of adherence to the advice given |
2 years |
|
Secondary |
Change in knowledge |
Women will complete questionnaires before and after the intervention to assess changes in knowledge about CMV |
2 years |
|
Secondary |
Knowledge of CMV risk reduction measures |
Women will complete questionnaires before and after the intervention to assess changes in knowledge about risk reduction measures and self-efficacy towards these |
2 years |
|
Secondary |
Acceptability of prevention measures |
Women will complete questionnaires before and after the intervention to assess the acceptability of prevention measures and to identify barriers to adherence. Interviews will also be carried out to explore these in more depth. |
2 years |
|
Secondary |
Acceptability of the educational intervention (film) |
Perceptions Perceptions and acceptability of the educational intervention will be explored in questionnaires and interviews |
2 years |
|
Secondary |
Anxiety level |
Women in the treatment arm will complete the Perinatal Anxiety Screening Scale and Edinburgh Depression Scale to ensure that study participation does not increase anxiety. |
2 years |
|